Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.
|
1 |
Ahlgren G et al. |
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised. Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
|
|
2 |
Ali A et al. |
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
|
|
3 |
Aula H et al. |
Decreases in TGF-ß1 and PDGF levels are associated with echocardiographic changes during adjuvant radiotherapy for breast cancer.
|
|
4 |
Boman E et al. |
Monte Carlo investigation on the effect of air gap under bolus in post-mastectomy radiotheraphy.
|
|
5 |
Boman E et al. |
Dosimetric comparison of surface mould HDR brachytherapy with VMAT.
|
|
6 |
Chaikc A et al. |
Dosimetrical and radiobiological approach to manage the dosimetric shift in the transition of dose calculation algorithm in radiation oncology: how to improve high quality treatment and avoid unexpected outcomes?
|
|
7 |
Gillessen S et al. |
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
|
|
8 |
Haltia O et al. |
The indirect costs of palliative care in end-stage cancer: A real-life longitudinal register- and questionnaire-based study.
|
|
9 |
Hermunen K et al. |
Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
|
|
10 |
Hietanen T et al. |
Natural Killer Cell Viability After Hyperthermia Alone or Combined with Radiotherapy with or without Cytokines.
|
|
11 |
Joensuu H et al. |
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
|
|
12 |
Joensuu H et al. |
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. The SOLD Randomized Clinical Tria.
|
|
13 |
Kaikkonen E et al. |
ANO7 is associated with aggressive prostate cancer.
|
|
14 |
Koivumäki T et al. |
Dosimetric evaluation of modern radiation therapy techniques for left breast in deep-inspiration breath-hold.
|
|
15 |
Korpi S et al. |
Therapeutic Procedures for Malignant Ascites in a Palliative Care Outpatient Clinic.
|
|
16 |
Koski K et al. |
Simulated Encounters With Vaccine-Hesitant Parents: Arts-Based Video Scenario and a Writing Exercise.
|
|
17 |
Luhtala S et al. |
Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer.
|
|
18 |
Luhtala S et al. |
Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
|
|
19 |
Motzer R et al. |
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
|
|
20 |
Mäkitie A et al. |
The management and survival outcomes of nasopharyngeal cancer in the Nordic countries.
|
|
21 |
Pajamäki N et al. |
Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer.
|
|
22 |
Piili R et al. |
Does special education in palliative medicine make a difference in end-of-life decision-making?
|
|
23 |
Piili R et al. |
Changes in attitudes towards hastened death among Finnish physicians over the past sixteen years.
|
|
24 |
Pollari M et al. |
PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.
|
|
25 |
Prusila REI et al. |
R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma.
|
|
26 |
Rahko E, Lehto J. |
Eutanasia.
|
|
27 |
Rajala K et al. |
Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life.
|
|
28 |
Rossi M et al. |
Dosimetric effects of anatomical deformations and positioning errors in VMAT breast radiotherapy.
|
|
29 |
Ruuskanen M et al. |
Outcome of nasopharyngeal carcinoma in Finland: A nationwide study.
|
|
30 |
Saarto T et al. |
Palliatiivinen hoito ja saattohoito. Päivitystiivistelmä.
|
|
31 |
Schmidt M et al. |
Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.
|
|
32 |
Sormunen J. |
Physical Activity and Incidence of Cancer with Special Emphasis on Colorectal and Prostate Cancers in Men.
|
|
33 |
Sormunen J et al. |
Perceived Physical Strain at Work and Incidence of Prostate Cancer – a Case-Control Study in Sweden and Finland.
|
|
34 |
Sperinde J et al. |
p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
|
|
35 |
Sunela K. |
Solunsalpaajahoitojen jälkeiset myöhäishaitat.
|
|
36 |
Talibov M et al. |
Benzene exposure at workplace and risk of colorectal cancer in four Nordic countries.
|
|
37 |
Tuohinen S et al. |
Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer.
|
|
38 |
Tuohinen S et al. |
Associations between ECG changes and echocardiographic findings in patients with acute non-ST elevation myocardial infarction.
|
|
39 |
Tuohinen S et al. |
Syövän hoitojen sydänvaikutukset.
|
|
40 |
Vanhanen A et al. |
Localization accuracy of two electromagnetic tracking systems in prostate cancer radiotheraphy: A comparison with fiducial marker based kilovoltage imaging.
|
|
41 |
Viitala A et al. |
The Coping and Support Needs of Incurable Cancer Patients.
|
|
42 |
Vänskä M et al. |
Osaatko epäillä hemofagosyyttistä lymfohistiosytoosia?
|
|
43 |
Wu X et al. |
Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage.
|